Intuitive Surgical filings document operating results, governance matters, capital structure, and material events for a Nasdaq-listed medical technology company focused on robotic-assisted surgery. Its Form 8-K reports furnish quarterly and preliminary financial results, procedure information, and exhibits tied to da Vinci and Ion business performance.
Regulatory filings also cover shareholder voting matters, proxy governance, executive compensation, director elections, and officer-role changes. Other material-event disclosures record completed corporate actions, including the acquisition of da Vinci and Ion distribution operations in Europe, alongside formal disclosures about common stock and financial reporting matters.
Intuitive Surgical’s Chief Executive Officer and director David J. Rosa reported grants of performance stock units that have now been earned based on previously set goals. On January 28, 2026, he acquired 6,360 PSUs from a February 26, 2024 grant, 9,575 PSUs from a February 28, 2023 grant, and 6,034 PSUs from a June 12, 2023 grant.
The compensation committee confirmed that the performance criteria for each grant were achieved. These PSUs convert into common stock if Rosa remains in continuous service through the vesting dates: February 26, 2027 for the 2024 grant and February 28, 2026 for the 2023 and June 2023 grants.
Intuitive Surgical EVP & Chief Medical Officer Myriam Curet reported option and stock transactions plus performance stock units. On January 29, 2026, she exercised 126 non-qualified stock options at $208.9 per share and sold 126 common shares at $520.02 per share under a Rule 10b5-1 trading plan that expires July 29, 2026.
Following these trades, she reported no directly held common stock and 353 common shares held indirectly through a trust. Separately, on January 28, 2026, 5,585 performance stock units granted on February 28, 2023 were reported after the company confirmed performance goals were achieved; these PSUs are scheduled to vest on February 28, 2026, subject to continued service.
Intuitive Surgical director Gary S. Guthart reported new performance-based equity awards. On January 28, 2026, he acquired 8,267 performance stock units (PSUs) tied to a February 26, 2024 grant and 17,556 PSUs tied to a February 28, 2023 grant, each at an exercise price of $0.0.
The Compensation Committee determined that the performance goals for both PSU grants were achieved. The 2024 grant PSUs are scheduled to vest on February 26, 2027, and the 2023 grant PSUs are scheduled to vest on February 28, 2026, in each case if Guthart remains in continuous service to Intuitive Surgical through those dates.
Intuitive Surgical executive Henry L. Charlton, EVP & Chief Commercial and Marketing, reported the achievement of performance conditions for two performance stock unit (PSU) awards. One award covers 2,861 PSUs granted on February 26, 2024, vesting on February 26, 2027, subject to continued service. The second covers 7,182 PSUs granted on February 28, 2023, vesting on February 28, 2026, also conditioned on ongoing employment.
Intuitive Surgical executive Jamie Samath, EVP & CFO & Enterprise Technol, reported performance stock unit awards tied to prior grants. On January 28, 2026, 3,180 PSUs from a February 26, 2024 grant and 7,182 PSUs from a February 28, 2023 grant were credited after performance criteria were achieved.
The 2024 grant PSUs vest on February 26, 2027, and the 2023 grant PSUs vest on February 28, 2026, in each case subject to Samath’s continuous service to Intuitive Surgical through the respective third-anniversary vesting dates.
ISRG security holder Curet McAdams filed a Rule 144 notice to sell 126 shares of common stock through Morgan Stanley Smith Barney on NASDAQ, with an aggregate market value of $65,522.52. The shares were acquired on 01/29/2026 via a stock option exercise paid in cash.
The notice states 354,496,073 shares of common stock outstanding and an approximate sale date of 01/29/2026. Over the prior three months, Curet McAdams sold additional common shares in several transactions, each with disclosed share amounts and gross proceeds.
Intuitive Surgical EVP & Chief Medical Officer Myriam Curet reported option exercises and stock sales in Intuitive Surgical, Inc. common stock. On January 27, 2026, she exercised options for 105 shares at $229.39 and 125 shares at $208.90, then sold 105 shares and 125 shares at $532.61 per share.
The filing notes these trades occurred under a Rule 10b5-1 trading plan that expires on July 29, 2026. After these transactions, the report shows 251 and 1,362 non-qualified stock options remaining directly held and 353 common shares held indirectly by a trust.
Intuitive Surgical director Gary S. Guthart reported an option exercise and related share sales. On January 27, 2026, a non-qualified stock option for 25,500 shares was exercised at $174.2567 per share, increasing his directly held common stock to 28,194 shares.
That same day, 24,500 common shares held directly were sold at a weighted average price of $530.0981, leaving 3,694 directly held shares. In addition, 1,400 shares were sold from a trust for his daughter and 1,400 shares from a trust for his son, each at weighted average prices just above $531, with 15,720 shares remaining in each child’s trust and 1,231,890 shares indirectly held by a separate trust. The filing notes these transactions were carried out under a Rule 10b5-1 trading plan that expires on April 28, 2026.
A planned insider sale has been filed for ISRG common stock under Rule 144. The notice covers the proposed sale of 24,500 common shares through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $12,987,403.45 at the time of filing.
The shares to be sold were acquired on 01/27/2026 via a stock option exercise, paid in cash, involving the same 24,500 shares. The filing also shows that Gary S. Guthart sold 22,806 common shares on 12/01/2025 for $13,019,721.90 in gross proceeds during the prior three months.
A shareholder of ISRG has filed a notice of proposed sale under Rule 144 to sell 230 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services. The shares to be sold have an aggregate market value of $122,500.30, while 354,496,073 shares of the issuer’s common stock are reported as outstanding. The planned sale date is listed as 01/27/2026 on the NASDAQ market, and the shares were acquired on the same date via a stock option exercise paid in cash.
The filer also reports prior sales of the issuer’s common stock during the past three months, including a transaction on 10/28/2025 in which 7,562 shares were sold for $4,147,192.12 in gross proceeds. By signing, the seller represents that they are not aware of any material adverse, non‑public information about the issuer’s current or prospective operations.